Author: Elena Morales

In recent years, the healthcare industry has been evolving rapidly, influenced by a combination of technological advancements, the need for more personalized patient care, and a greater demand for convenient healthcare solutions. As part of this transformation, telehealth services and compounding pharmacies have seen significant growth and increasingly integrated their offerings to meet patients’ specific medical needs. This article delves deeper into the key developments and trends within the compounding pharmacy market, highlighting major players, recent moves, and the market’s projected growth.

The Growing Compounding Pharmacy Market: Trends and Forecasts

The compounding pharmacy market, which involves the creation of personalized medications for individual patients, has gained considerable traction due to the rising demand for tailored therapeutic solutions. In 2023, the global compounding pharmacy market size was valued at US$ 13.19 billion. Projections indicate that the market will grow at a compound annual growth rate (CAGR) of 5.15%, reaching a size of US$ 22.91 billion by 2034. This growth is driven by several factors, most notably the increasing patient demand for high-quality, specialized medications that cannot be found in standard pharmaceutical offerings.

Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5338

As the global healthcare system moves toward a more patient-centric approach, compounded medications are filling critical gaps in patient care. For example, patients with specific allergies, sensitivities to certain ingredients, or those who require medications in unique dosages or delivery methods (such as creams, liquids, or gels) benefit from the personalized services offered by compounding pharmacies. This demand is expected to grow exponentially, especially as new therapies for chronic conditions, hormone imbalances, and pain management continue to emerge.

Hims & Hers: Expanding into the Compounding Pharmacy Sector

A standout development in the telehealth space came in August 2024 when Hims & Hers, a leading telehealth company known for its focus on mental health, sexual health, and weight-loss medications, made a significant strategic decision to diversify its offerings. The company announced its acquisition of a compounding pharmacy, marking its foray into the personalized medicine sector.

This acquisition reflects a larger trend in telehealth companies recognizing the importance of offering not just consultations but also customized treatments. By acquiring a compounding pharmacy, Hims & Hers can now provide its patients with medications tailored to their specific needs, such as hormone therapies, specialized pain medications, or customized skincare treatments. This move allows Hims & Hers to strengthen its position in the healthcare space by offering an integrated approach, where patients can consult with healthcare professionals and simultaneously receive bespoke prescriptions, all through an accessible telemedicine platform.

Hims & Hers’ expansion into compounding pharmacy operations represents a growing trend of telehealth companies integrating more services, blurring the lines between digital health consultations and traditional pharmacy services. By creating a more comprehensive healthcare ecosystem, the company aims to improve patient outcomes through a holistic, personalized approach.

Revelation Pharma: Nationwide Expansion and Wholesale Services

Another significant player in the compounding pharmacy market, Revelation Pharma, made waves in September 2024 by announcing the expansion of its nationwide compounding network. Revelation’s 503A and 503B compounding pharmacies now offer Revelation Wholesale, a nationwide service tailored to healthcare providers who require specialty drugs and compounded medications for their patients.

This expansion is an essential response to the increasing demand for specialty drugs, particularly in the treatment of complex health conditions where off-the-shelf medications may not suffice. Revelation Wholesale simplifies the ordering process for healthcare providers, making it easier for them to access high-quality compounded medications without having to navigate the complexities of dealing with multiple suppliers.

Revelation Pharma’s initiative is a reflection of the growing market trend in compounding pharmacies: to not only serve individual patients but also streamline supply chains for healthcare professionals. By providing a bulk supply service, Revelation is tapping into the needs of the broader healthcare ecosystem, ensuring that pharmacies and clinicians have easier access to the customized medications they require. This further boosts the accessibility and availability of compounded medicines.

Precision Compounding: Investment Boost for Telemedicine Integration

In November 2023, Precision Compounding Pharmacy received a notable investment from Right Side Capital Management, a technology startup investment group. Precision Compounding is renowned for its integration of telemedicine with pharmacy services, allowing patients to receive compounded medications prescribed through virtual consultations.

The infusion of capital from Right Side Capital Management is expected to fuel the company’s growth and enable it to assist more patients through its telehealth and telepharmacy services. The unique model of Precision Compounding — which blends telemedicine with personalized drug dispensing — reflects the growing intersection between technology and healthcare, helping bridge the gap between remote consultations and personalized prescriptions.

This investment will enable Precision Compounding to scale its operations, expanding its reach to more patients in need of specialized compounded treatments. It is an example of how technology-driven solutions are reshaping the compounding pharmacy industry, enhancing both patient access and medication delivery efficiency.

The Role of Compounding Pharmacies in Personalized Medicine

Compounding pharmacies specialize in creating customized medications for patients based on their unique medical needs. These pharmacies can create formulations that are not commercially available, providing tailored solutions for conditions that require specialized drug delivery methods or dosages. This personalized approach allows patients to receive medication in a form that best suits their preferences or medical conditions, whether it is a specific dosage, an allergy-free ingredient, or a form such as a transdermal cream, suppository, or liquid.

In addition to their ability to cater to specific patient needs, compounding pharmacies play an essential role in treating rare or niche conditions that require medications not found in mainstream pharmaceutical offerings. Whether it’s creating a custom dosage of a life-saving drug or formulating a medication for a child with difficulty swallowing pills, compounding pharmacies offer flexibility and precision in a way that traditional pharmacies cannot.

Several key companies are leading the charge in providing these personalized services:

• Fagron: A global leader in the compounding pharmacy industry, offering a broad range of custom formulations.
• Formul8: Specializes in providing personalized medications for both patients and healthcare providers.
• Walgreen Co.: As one of the largest retail pharmacy chains, Walgreens has expanded its compounding services, offering a wider array of custom-made medications.
• MEDS Pharmacy: Focuses on patient-centered compounding solutions, emphasizing quality and safety in every product.
• Fusion Apothecary: Known for its dedication to patient safety, Fusion offers a variety of compounded medications.
• Aurora Compounding: Offers specialized compounding services for a wide range of conditions, including dermatological and hormone therapies.
• Albertsons Companies: Expanding into compounding services as part of a broader healthcare approach.
• Apollo Clinical Pharmacy: Specializes in custom-made medications with a focus on precision and patient outcomes.
• Galenic Laboratories Limited (Roseway Labs): Provides solutions for both pharmaceutical and nutraceutical needs.
• The London Specialist Pharmacy Ltd (Specialist Pharmacy): Offers high-quality compounded medications, particularly for chronic conditions.
• JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy): Focuses on providing personalized care with a strong emphasis on patient needs.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/compounding-pharmacy-market-sizing

Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5338

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Bioinformatics is a dynamic and evolving field that blends computational technology with biological sciences to analyze, store, and interpret complex biological data. By integrating various scientific and technological domains, bioinformatics facilitates the understanding of molecular biology, particularly the expression and regulation of genes and proteins. It also plays a key role in deciphering evolutionary relationships and in structural biology, where it supports the simulation and modeling of DNA, RNA, proteins, and biomolecular interactions. One of the field’s most remarkable achievements has been the analysis of genome sequence data, especially in the context of large-scale projects like the Human Genome Project.

Bioinformatics in Drug Discovery and Health Research

The need for bioinformatics is on the rise due to its vital role in drug discovery and the identification of new drug targets. As scientists continue to explore and unlock the complexities of human biology, bioinformatics provides the computational tools required to process vast amounts of biological data. Advances in DNA sequencing technologies and the expanding breadth of biological research are driving this demand. Researchers are now leveraging bioinformatics to gain deeper insights into human health, which is expected to enhance our understanding of diseases and lead to more effective treatments.

One of the key areas in which bioinformatics plays an integral role is genomics. As the ability to sequence DNA has improved, bioinformatics tools have become essential for processing and interpreting genomic data. These tools help scientists understand the functions and roles of genes and proteins in human biology. Additionally, bioinformatics aids in predicting how changes in DNA sequences might influence disease susceptibility, which can inform the development of targeted therapies.

Another area of bioinformatics impact is its role in understanding the molecular underpinnings of diseases, including cancer, cardiovascular diseases, and infectious diseases. By analyzing complex data sets that include genetic, proteomic, and transcriptomic information, bioinformatics allows researchers to pinpoint potential drug targets and biomarkers, accelerating the drug discovery process. The integration of technologies like artificial intelligence (AI) and machine learning (ML) has further transformed the bioinformatics landscape, making it possible to analyze vast amounts of biological data more efficiently.

Market Growth and Investment Opportunities

The bioinformatics market has experienced impressive growth in recent years and is poised to continue expanding at a rapid pace. The global bioinformatics market was valued at US$ 11.53 billion in 2023 and is projected to grow to US$ 47.48 billion by 2034, rising at a compound annual growth rate (CAGR) of 13.73% from 2024 to 2034. This growth is driven by the increasing demand for genomic and proteomic research, the development of novel drug discovery and therapies, and technological advancements in computational tools and infrastructure.

Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5337

Government support has significantly contributed to the growth of the bioinformatics market. Policies encouraging research in genomics, proteomics, metabolomics, and transcriptomics have fostered an environment where bioinformatics solutions can thrive. For example, in September 2024, the World Health Organization (WHO) conducted a workshop aimed at improving genomic surveillance and bioinformatics analysis for respiratory viruses. The goal was to enhance the global capacity for genomic surveillance under the Global Influenza Surveillance and Response System (GISRS), ensuring that bioinformatics plays a critical role in managing global health challenges.

In addition, private companies are driving innovations in bioinformatics services. In September 2024, Almaden Genomics launched a new Data Management and Informatics Services business, designed to support bioinformatics and computational biology solutions. This new service addresses the challenges faced by researchers, pharmaceutical companies, and biotech organizations in handling large-scale genomic data.

Furthermore, advancements in genome sequencing technologies are also fueling the bioinformatics market. In August 2024, Inocras, Inc. introduced whole genome sequencing services powered by the UG 100 sequencer from Ultima Genomics, Inc., further expanding the capabilities of bioinformatics solutions in both research and healthcare.

AI and Machine Learning: Transforming Bioinformatics

The integration of AI and ML has revolutionized the bioinformatics field. These technologies are increasingly being used to interpret complex genomic and proteomic data, making it more accessible and usable for researchers. AI applications in bioinformatics range from the use of natural language processing (NLP) for aggregating and translating biological research, to artificial neural networks that classify gene expression profiles, predict protein structures, and even assist in DNA sequencing.

AI and ML enable bioinformatics platforms to process large volumes of biological data, reducing the time and costs associated with drug discovery. By automating data analysis and prediction tasks, AI and ML make it possible to identify potential drug candidates more rapidly, which is particularly valuable in the pharmaceutical industry. This acceleration of the drug discovery process promises to have significant implications for healthcare, particularly in the development of personalized medicines and targeted therapies.

Challenges Facing the Bioinformatics Market

Despite the numerous benefits and advancements in the bioinformatics field, several challenges remain. One of the major hurdles is computational complexity. Bioinformatics involves working with large-scale datasets, which require substantial computational power and infrastructure. High-performance systems are necessary to manage and analyze this data, but they come at a significant cost, limiting accessibility for researchers in developing and underdeveloped countries.

Another significant challenge is the lack of trained professionals in bioinformatics. While the field is growing rapidly, many scientists and engineers, particularly in low- and middle-income countries (LMICs), lack the necessary skills and expertise to effectively utilize bioinformatics tools. This shortage of skilled professionals poses a barrier to the widespread adoption of bioinformatics and limits its potential in global health research and drug development.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/bioinformatics-market-sizing

Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5337

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The DNA sequencing market is experiencing rapid advancements, driven by increasing investments, technological innovations, and favorable government policies. In 2023, the market size was estimated at USD 12.42 billion and is projected to reach USD 107.63 billion by 2034, growing at a compound annual growth rate (CAGR) of 21.69% from 2024 to 2034. This growth is primarily fueled by the rising demand for genomics research, technological advancements, and an influx of investments into the biotechnology and healthcare sectors. Key regions, including North America and Asia-Pacific, are leading this growth, each contributing uniquely to the expansion of the DNA sequencing market. This article explores the regional insights, segmental trends, and factors influencing the market’s progress.

Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5336

Regional Insights

North America: Dominated by Favorable Government Policies

In 2023, North America held the largest share of the global DNA sequencing market, and it is expected to continue its dominance over the forecast period. The region’s robust presence of key industry players, coupled with rising incidences of rare disorders and cancers, plays a significant role in propelling market growth. Additionally, state-of-the-art research and development (R&D) facilities contribute to this expansion.

A key driver of growth in North America is the active involvement of the US government in advancing DNA sequencing technology. The National Human Genome Research Institute (NHGRI) is a significant source of funding, supporting various research institutions and organizations working on DNA sequencing initiatives. Notably, in August 2024, the US Food and Drug Administration (FDA) announced plans to use whole genome sequencing to protect consumers from foodborne illnesses on a global scale.

On the Canadian front, the government’s investment of $15 million over five years for the development of a national genomic data management system—the Pan-Canadian Genome Library (PCGL)—is set to boost the region’s DNA sequencing capabilities.

Asia-Pacific: Rapid Growth Fueled by Investments and Demographics

Asia-Pacific is set to be the fastest-growing region for the DNA sequencing market. The region benefits from a rising geriatric population, rapidly changing demographics, increasing investments, and supportive government policies. The Chinese government’s Five-Year Plan (2021-2025) is aimed at strengthening the biotechnology sector, contributing over 10% of the region’s R&D investment.

In addition, the Genome India Project, launched by the Department of Biotechnology, has successfully sequenced 10,000 Indian genomes as of March 2024. This initiative has fueled a 13-fold increase in bio-economy growth over the past decade, positioning India as one of the top 12 bio-manufacturers globally. These developments indicate a booming DNA sequencing landscape in Asia-Pacific, which is further bolstered by ongoing advancements in biotechnology and genomics.

Segmental Insights

By Product: Consumables and Services Lead the Market

The consumables segment dominated the DNA sequencing market in 2023, including essential reagents, buffers, and purification solutions for DNA sequencing. As genomics research continues to grow, the demand for consumables is expected to rise, along with ongoing innovations in sequencing technologies that further drive the segment’s growth.

Simultaneously, the services segment is anticipated to grow at the fastest rate during the forecast period. Sequencing services are increasingly preferred for their time-saving advantages and high accuracy, as the experiments are carried out by highly skilled technical experts.

By Technology: Next-Generation Sequencing (NGS) Dominates, Third-Generation Sequencing Shows Promise

In 2023, next-generation sequencing (NGS) technology held the largest share of the DNA sequencing market. NGS is valued for its ultra-high throughput, scalability, speed, and versatility in DNA/RNA sequencing and variant detection. However, third-generation sequencing (TGS) is expected to grow at the highest compound annual growth rate (CAGR) during the forecast period. TGS offers enhanced diagnostic accuracy, speed, and efficiency, positioning it as a key technology in the DNA sequencing market’s future.

By Workflow: Sequencing and Data Analysis Lead

The sequencing segment led the market in 2023. Sequencing is a crucial step in DNA analysis, where nucleotides are read on a sequencer to generate data. As the demand for genomics research grows, the sequencing segment is expected to maintain its leadership.

The data analysis segment is projected to experience rapid growth in the coming years. Data analysis, which involves interpreting sequencing data using advanced bioinformatics tools, is essential for understanding the results of sequencing experiments. Innovations in software and the evolution of graphic user interfaces are expected to contribute significantly to the growth of this segment.

By Application: Oncology and Consumer Genomics on the Rise

Oncology was the dominant application segment in 2023. The increasing global incidence of cancer has spurred the demand for early detection, with DNA sequencing playing a critical role in identifying cancer markers and predicting cancer risks, including in infants. As awareness and demand for precision medicine grow, oncology will remain a key application for DNA sequencing.

Meanwhile, the consumer genomics segment is poised for rapid growth. Increasing awareness about genetic predispositions to diseases, particularly in neonates, and the continued development of sequencing technologies are key drivers of this segment’s expansion.

By End-Use: Academic and Clinical Research Set for Growth

In 2023, academic research dominated the DNA sequencing market. Increased funding from both government and private organizations, as well as the growing number of symposiums and conferences for academic researchers, are contributing to the sector’s growth.

The clinical research segment is expected to expand rapidly in the coming years. Technical expertise, favorable infrastructure, and sufficient funding are all fueling this sector’s development. DNA sequencing in clinical research is playing a pivotal role in diagnostics, personalized medicine, and treatment planning.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/dna-sequencing-market-sizing

Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5336

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

North America: Dominance Driven by Key Players and Innovation

In 2023, North America held the largest share of the global long read sequencing market, driven by the region’s advanced infrastructure, high level of investments, and the presence of key players in the genomics and biotechnology sectors. Major companies such as PacBio, Azenta, Thermo Fisher Scientific, and Illumina lead the charge, offering state-of-the-art sequencing solutions that support both research and clinical applications.

The market in North America is further fueled by substantial investments in research and development, especially in novel drug discovery and personalized medicine. Increasing awareness around the benefits of personalized treatments, combined with the growing demand for precise genetic analysis, is boosting the adoption of LRS technologies.

A significant driver for the region is the favorable government policies and regulatory approvals for personalized medicines. In 2022, the U.S. FDA approved 12 novel personalized medicines, accounting for 34% of all newly approved therapeutics. Notably, five of these were new cell and gene therapies, underscoring the demand for advanced sequencing technologies like LRS that support genomic research, drug discovery, and clinical diagnostics. These factors, along with ongoing collaborations and partnerships in biotechnology and pharmaceuticals, are expected to ensure North America’s continued dominance in the market.

Asia-Pacific: Rapid Growth Powered by Government Initiatives

The Asia-Pacific (APAC) region is projected to witness the fastest growth in the long read sequencing market over the coming years. This surge is driven by the rising geriatric population, the increasing prevalence of genetic and chromosomal disorders, and the growing research and development activities in the region. As genomics and precision medicine continue to gain traction, countries like India, China, and Japan are increasingly leveraging LRS technologies for research and healthcare applications.

One of the key factors contributing to the growth in Asia-Pacific is the supportive government policies aimed at fostering genomics and precision medicine. In January 2024, India’s GenomeIndia Project completed the whole genome sequencing of 10,074 individuals across 99 communities, making a significant contribution to the country’s genomic research capabilities. Similarly, China’s government has long been at the forefront of supporting genomic research. In 2016, it announced a $9 billion, 15-year initiative to collect, analyze, and sequence genomic data, aiming to position itself as a global leader in precision medicine.

In Japan, the government has been focused on advancing genomic research through a variety of initiatives, including collaborations with international research communities. These government-driven projects, paired with the region’s rapidly evolving healthcare infrastructure, are expected to accelerate the adoption of LRS technologies.

Europe: Strong Research Infrastructure and Collaborative Efforts

While North America currently leads the market, Europe is also a significant player in the long read sequencing market. The region boasts a strong research infrastructure and a well-established healthcare system that supports genomic research and clinical diagnostics. Countries such as the United Kingdom, Germany, and France are home to world-renowned universities, research institutions, and biotechnology companies that drive innovation in LRS technology.

Europe’s market growth is primarily fueled by its commitment to advancing personalized medicine, with precision therapies and genomic data analysis becoming essential components of healthcare systems. As part of Horizon Europe, the EU is actively investing in large-scale genomic initiatives and clinical trials, which are expected to contribute to the increasing adoption of LRS.

Additionally, collaborations between public and private sector entities within Europe continue to foster advancements in LRS applications, making the region a strong contender in the market’s future growth.

Latin America and the Middle East & Africa: Emerging Markets with Growth Potential

While Latin America (LA) and the Middle East & Africa (MEA) currently hold smaller shares of the global long read sequencing market, both regions present growth potential. In Latin America, countries such as Brazil and Mexico are beginning to explore the benefits of advanced sequencing technologies. The rising incidence of genetic disorders and the growing focus on personalized medicine are pushing the demand for LRS solutions in the region.

In the Middle East and Africa, countries such as Saudi Arabia, the United Arab Emirates, and South Africa are investing heavily in healthcare infrastructure and research. Governments in these regions are recognizing the importance of genomic medicine and have started to promote initiatives aimed at enhancing genomic research capabilities. As these regions continue to expand their healthcare and biotechnology sectors, the long read sequencing market is expected to experience gradual but steady growth.

Long Read Sequencing Market Growth

The Long Read Sequencing (LRS) market is on a rapid upward trajectory, with its value estimated at US$ 0.6 billion in 2023 and expected to reach US$ 11.6 billion by 2034, growing at an impressive compound annual growth rate (CAGR) of 30.96% from 2024 to 2034. This growth is fueled by factors such as the rising incidences of genetic disorders, expanding research and development efforts, and the increasing demand for personalized medicines. As the market evolves, several key segments are emerging as dominant players, while others are set to experience significant growth in the coming years. This article explores these dynamics, breaking down insights by product, technology, workflow, application, and end-use segments.

Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5324

Product Segmentation

In 2023, the consumables segment emerged as the dominant force in the LRS market. Consumables for LRS, which include flow cells, assay kits, and reagents, play a critical role in the sequencing process. These products offer a cost-effective and flexible alternative, eliminating the need to purchase entire sequencing kits. The increasing demand for consumables highlights the growing utilization of LRS in genomic research across diverse fields.

However, the services segment is expected to grow at the fastest rate during the forecast period. The shortage of trained professionals, combined with the availability of favorable infrastructure in smaller research institutions, has led to a surge in demand for LRS services. These services save valuable time for researchers, allowing them to focus on outcomes rather than the intricate procedural details of sequencing.

Technology Trends

In 2023, nanopore sequencing was a key player, holding a significant share of the global LRS market. This sequencing technology stands out because it allows real-time analysis in fully scalable formats. Nanopore sequencing is capable of analyzing native DNA or RNA, making it versatile and efficient for various applications. Moreover, it works with a variety of input materials, such as genomic DNA, amplified DNA, cDNA, and native RNA, which further enhances its versatility in genomic research.

On the horizon, single molecule real-time (SMRT) sequencing is expected to witness substantial growth. SMRT sequencing reduces the need for chemical modifications during library preparation and eliminates DNA amplification. This technology offers an additional benefit by enabling the detection of epigenetic modifications, which is crucial for understanding complex biological processes.

Workflow Insights

By workflow, the sequencing segment led the global LRS market in 2023. Sequencing remains an essential step in LRS, involving the reading of nucleotides on a sequencer at a specified read length and depth. During this process, clonal clusters are detected base by base, ensuring high accuracy in genetic analysis.

The data analysis segment, however, is anticipated to grow at the highest CAGR during the forecast period. As sequencing technology advances, the need for robust data analysis solutions grows. The data analysis phase, which involves read processing and sequence analysis, plays a crucial role in interpreting complex genomic data, further driving demand for sophisticated analysis tools and software.

Application Areas

In terms of application, whole genome sequencing was dominant in 2023. This technique has gained significant traction due to its ability to cater to the rising demand for personalized medicine, identification of causative genetic variants, and novel genome assembly. Whole genome sequencing provides a comprehensive understanding of an individual’s genetic makeup, paving the way for advancements in precision medicine.

Meanwhile, the metagenomics segment is predicted to experience rapid growth in the coming years. The rising incidence of chronic disorders, coupled with disease prognosis research and novel drug discovery, is expected to drive demand for metagenomic sequencing. This application, which focuses on studying genetic material directly from environmental samples, is essential for exploring microbial communities and their role in human health.

End-Use Applications

The academic and research institutes segment dominated the LRS market globally in 2023. This segment’s growth is driven by the continued expansion of research and development activities, as well as the increasing number of scientific publications and patents related to LRS technology. These institutions remain the largest consumers of LRS technology, using it for a wide array of genomic studies.

Looking forward, the pharmaceutical and biotechnology companies segment is poised to grow at the fastest rate during the forecast period. These companies benefit from well-established infrastructure, significant funding, and state-of-the-art research facilities, which enable them to leverage the full potential of LRS. The demand for LRS in drug discovery, clinical trials, and personalized medicine is expected to further propel this segment’s growth.

Market Outlook and Expert Analysis

The long read sequencing market is undergoing a remarkable transformation, with projections indicating robust growth in the coming decade. The estimated market size of US$ 0.6 billion in 2023 is expected to surge to US$ 11.6 billion by 2034, propelled by the growing incidence of genetic disorders and the increasing emphasis on precision medicine. The rise in genomic research and demand for more personalized treatments are the primary driving forces behind this rapid expansion. Additionally, the rapid advancements in sequencing technologies, such as nanopore and SMRT sequencing, are expected to play a crucial role in the market’s evolution.

Experts foresee continued advancements in LRS technology that will further enhance its applications in clinical diagnostics, drug discovery, and disease research. The expansion of services, particularly in small research institutions and clinical settings, will also contribute significantly to market growth. With the ongoing advancements in both technology and application, the LRS market is positioned for significant expansion, providing numerous opportunities for research, healthcare, and biotechnology sectors.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/long-read-sequencing-market-sizing

Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5324

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The global biomarkers market was valued at US$ 82.35 billion in 2023 and is projected to reach US$ 366.6 billion by 2034, growing at a compound annual growth rate (CAGR) of 14.54% from 2024 to 2034. This growth is driven by the increasing incidence of chronic diseases, advancements in research and development, and rising investments in the sector.

Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5322

Favorable Government Policies Dominate North America

North America continues to lead the biomarkers market due to state-of-the-art research infrastructure and strong government support. The US Food and Drug Administration (FDA) has been pivotal in integrating biomarkers into medical product development and approval processes. This initiative accelerates the development of new therapeutics, making the region a hub for biomarkers-related research.

The Canadian government has also made substantial contributions through initiatives like the Canadian Health Measures Survey (CHMS), which monitors human biomonitoring data and collaborates with Health Canada and the Public Health Agency of Canada. Such programs facilitate the collection of vital data that supports biomarker research and development. Together, these favorable policies create a conducive environment for the market’s growth in North America.

Rising Incidences of Chronic Disorders Drive Asia-Pacific Growth

Asia-Pacific is forecasted to be the fastest-growing region for biomarkers in the coming years. The rapid rise in chronic disorders, along with increasing investments in research and development, is expected to fuel the demand for biomarkers in this region. The growing prevalence of diseases like cancer, immunological disorders, and neurological diseases is expected to propel the biomarkers market.

In countries like China, India, and Japan, the aging population and the high incidence of chronic diseases are creating a pressing need for biomarkers in disease diagnosis and drug discovery. For example, China alone has over 15 million people aged 60 and older living with dementia, while India reported 8.8 million cases, and Japan accounted for approximately 3.9 million cases in 2023. This demographic shift, combined with rapid urbanization, is expected to drive significant market expansion in the Asia-Pacific region.

Key Biomarker Types: Safety and Efficacy

In 2023, the safety biomarkers segment held a dominant position in the global biomarkers market. These biomarkers indicate potential toxicity or adverse effects of a medicinal product or environmental contaminant. They are often utilized in early clinical trials, playing a crucial role in the decision-making process and advancing promising therapeutics from preclinical to clinical development.

On the other hand, the efficacy biomarkers segment is projected to experience the fastest growth in the forecast period. These biomarkers are indicators of a drug’s therapeutic effects and are crucial in evaluating the early stages of disease progression and pharmacological changes.

Cancer and Neurological Disorders Drive Disease-Specific Growth

The cancer segment dominated the biomarkers market in 2023. This dominance is attributed to the increasing incidence of cancer, its complex nature, and the rising demand for personalized medicines. Biomarkers play a key role in cancer diagnosis, prognosis, and predicting the likelihood of disease recurrence, independent of treatment, which has led to significant market demand.

Similarly, the neurological diseases segment is anticipated to grow at a considerable compound annual growth rate (CAGR) due to the rising incidence of age-related neurological disorders such as Alzheimer’s and Parkinson’s diseases. With an increasingly aging population, the demand for biomarkers in neurological disease research is expected to surge.

Drug Discovery and Development: The Leading Application

By application, the drug discovery and development segment held the dominant share of the global biomarkers market in 2023. Biomarkers provide valuable insights into disease pathways, assisting in the identification of new therapeutic targets. With increasing awareness and investments in drug discovery, this segment is expected to continue its growth trajectory in the coming years.

Notably, the Digital Biomarkers Summit, scheduled for May 2024, will bring industry leaders together to foster collaboration and accelerate the adoption of digital biomarkers. Rinol Alaj, Senior Director of Digital Health Technologies at Regeneron, emphasized the importance of collaboration in advancing the digital biomarkers field.

Recent Research Advancements

Innovative research in biomarkers continues to push the boundaries of medical science. In October 2024, researchers from the Walter and Eliza Hall Institute explored the potential of extracellular vesicles as biomarkers for cancer treatment. They discovered abnormally high levels of extracellular vesicles in the blood of mice with leukemia, suggesting new pathways for diagnostic and therapeutic applications.

In another significant breakthrough, researchers from Nationwide Children’s Hospital identified a potential biomarker for single ventricle heart disease (SVHD) in fetuses. By analyzing maternal blood samples, they found elevated levels of cell-free miRNAs in mothers carrying babies with SVHD, opening new avenues for early diagnosis.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/biomarkers-market-sizing

Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5322

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

North America maintained its dominance in the global plasma fractionation market in 2023, with the United States standing as the largest supplier of plasma fractionation worldwide. A key factor contributing to this leadership is the United States’ policy of paid plasma donations, in contrast to many other countries that rely on volunteer or unpaid donors. This difference significantly impacts the plasma collection rate, with the U.S. enjoying a higher rate of plasma donations. In fact, U.S.-based plasma product companies, including CSL Plasma, Grifols, and BioLife, collect over 75% of the total plasma used for fractionation within the country. There has been a notable increase in the number of plasma donation centers in the U.S., with a 54% rise in the past four years alone. As the demand for plasma continues to grow, the country faces an ongoing need for consistent donation rates, estimated at 6,500 units of plasma per basis.

Canada also plays a crucial role in the global plasma market. The Canadian Blood Service utilizes raw plasma to produce vital plasma-derived products, including plasma proteins, which are essential in treating a range of conditions. As the demand for plasma continues to rise, North America is expected to maintain its leadership in the market for years to come.

Global Plasma Fractionation Market Size and Growth Outlook

The global plasma fractionation market was valued at approximately US$ 32.75 billion in 2023 and is projected to experience substantial growth over the next decade. With a compound annual growth rate (CAGR) of 7.54%, the market is expected to reach US$ 72.86 billion by 2034. This growth is being driven by the increasing therapeutic demand for plasma-derived products, which are essential in treating various medical conditions, from autoimmune diseases to bleeding disorders. As healthcare providers look to meet the growing need for plasma and its derivatives, the market continues to expand, particularly in regions like North America and Europe, where demand for these life-saving products is rising steadily.

Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5320

Europe: Anticipated Growth in Plasma Fractionation Market

In contrast, Europe is projected to experience the fastest growth in the plasma fractionation market over the next decade. This growth is largely influenced by the European Union’s focus on achieving open strategic autonomy and improving competitiveness in the healthcare sector. The European Union, alongside member states and private businesses, is taking action to enhance the resilience of the plasma supply chain. By addressing vulnerabilities and seizing opportunities, Europe aims to establish stronger policies for the supply of plasma and plasma-derived medicinal products. These efforts will support the EU in securing greater recognition in the global plasma fractionation market, creating a solid foundation for future growth.

Market Segment Insights: Dominance and Expansion

In terms of market segments, immune globulin products dominated the plasma fractionation market in 2023. Plasma-derived immunoglobulins have emerged as a crucial component in the healthcare industry, particularly in treating autoimmune inflammatory diseases. These immunoglobulins are vital for patients who are unable to produce sufficient antibodies, offering an externally sourced solution to support recovery.

The coagulation factor segment is expected to see significant growth during the forecast period from 2024 to 2034. Coagulation factors are essential in stopping bleeding after an injury, and their ability to control the conversion of plasma fibrinogen to fibrin, which forms a gel network to stop bleeding, makes them an indispensable part of plasma-derived medicines.

Hospital Segment: Plasma in Emergency Care

The hospital sector accounted for the largest share of the plasma fractionation market in 2023. Plasma is widely utilized in emergency settings to boost blood volume in trauma patients, prevent shock, and aid in blood clotting. Hospitals and other healthcare facilities depend on plasma-derived medicinal products to treat patients with immune deficiency disorders, including HIV, hepatitis, and other serious conditions.

Retail Pharmacy Segment: Fastest Growing Application

Looking ahead, the retail pharmacy sector is expected to grow at the highest compound annual growth rate (CAGR) in the plasma fractionation market. Pharmaceutical companies play a key role in extracting components from raw human plasma, using techniques like centrifugation, depth filtration, and chromatography. This advanced manufacturing process is designed to produce effective and safe medications for patients.

Recent Developments in Plasma Fractionation

Several noteworthy developments are shaping the future of plasma fractionation. In July 2024, Grifols, a leading Spanish pharmaceutical company known for its plasma-derived medicines, appointed Rahul Srinivasan as its new Chief Financial Officer. Srinivasan expressed gratitude for the opportunity to serve in this role, emphasizing Grifols’ impact on patients’ lives through its life-changing portfolio of medicines across various therapeutic areas.

In June 2024, Roland Wandeler, President of Grifols’ Biopharma Business Unit, praised Biotest’s Yimmungo for its potential to expand the availability of intravenous and subcutaneous immunoglobulins. These treatments are essential for patients with primary immunodeficiencies, who rely on immunoglobulin therapies for daily management.

Additionally, innovative collaborations are taking place in the field of plasma-derived therapies. In August 2024, Nanoform Finland partnered with Takeda Pharmaceutical Company to develop pre-clinical plasma-derived therapy formulations. Their collaboration aims to address rare medical conditions by enhancing the effectiveness of plasma-derived treatments.

A groundbreaking initiative was launched in September 2024 with the creation of a joint venture between Grifols and Egypt’s National Service Project Organisation (NSPO). The project aims to achieve self-sufficiency in plasma-derived medicine for Egypt, including the establishment of a plasma laboratory, warehouse, 20 donation centers, and a cutting-edge manufacturing facility. This ambitious national initiative is set to enhance the country’s ability to produce and supply plasma-derived medicines for the treatment of various medical conditions.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fractionation-market-sizing

Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5320

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The plasma fraction market has witnessed significant growth and innovation, with increasing demand for plasma-derived therapies addressing a wide range of medical conditions. This article explores the current market trends, segmental insights, and recent developments that are shaping the future of plasma-derived medicines.

Plasma Fraction Market Overview

The global plasma fraction market was valued at US$ 32.75 billion in 2023 and is projected to reach US$ 72.86 billion by 2034, growing at a CAGR of 7.54% from 2024 to 2034. This expansion is largely driven by the rising demand for plasma-derived medicines used in treating conditions like rabies, tetanus, shock, and trauma. As these life-threatening diseases continue to pose challenges, the need for effective therapeutic solutions derived from plasma is growing, fueling the market’s rapid development.

Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5304

Segmental Insights

By Type
In 2023, the immunoglobulin segment led the market, capturing the highest share. Plasma-derived immunoglobulin plays a pivotal role in the treatment of autoimmune inflammatory diseases, especially in conditions where the body requires recovery after an infectious attack like COVID-19. Immunoglobulins are essential for treating rare conditions, such as primary immunodeficiency, where they often represent the only viable treatment option.

The coagulation factors segment is anticipated to grow at the fastest pace during the forecast period. These products are crucial for treating blood clotting disorders such as hemophilia and Von Willebrand’s disease, leading to the increased demand for plasma-derived therapies in these areas.

By Application
The hospital segment dominated the plasma fraction market in 2023, thanks to the extensive use of plasma protein to treat a range of conditions in hospital settings. Plasma proteins are vital in managing trauma, burns, animal bites, shocks, major surgeries, hepatitis, RH incompatibility, organ transplants, pediatric HIV, and liver diseases.

Meanwhile, the retail pharmacy segment is expected to experience the fastest growth during the projected period. This growth is driven by a steady rise in human plasma donations and an increasing number of patients eligible for plasma-derived therapies, enhancing both supply and retail sales.

Industry Announcements

Dr. Ranjeet S. Ajmani, CEO of Aegros Asia, outlined a bold vision to transform plasma fractionation across Asia and other developing regions. His focus is on creating sustainable plasma fractionation models using the HeamaFrac process, addressing the critical issue of over 2 million liters of plasma being wasted annually in Asia. Through partnerships with blood centers, regulators, and local and international organizations, Aegros aims to provide consistent access to safe plasma-derived medicines and improve the quality of life for patients in these regions.

Recent Developments

• Grifols Collaboration with Orange Business:
  In September 2024, Grifols, a leading global healthcare company, joined forces with Orange Business to build a state-of-the-art data center for plasma derivative facilities in Egypt. The collaboration is set to enhance the sustainable supply of critical therapeutics for life-threatening diseases, ensuring that more patients have access to life-saving treatments.
• Kedrion Biopharma’s Commercialization Agreement:
  In July 2024, Kedrion Biopharma Inc. announced a long-term partnership with Biotest AG for the commercialization and distribution of Yimmungo®, an immunoglobulin therapy approved by the FDA in June 2024. This agreement strengthens Kedrion’s presence in the market and expands access to advanced immunoglobulin treatments.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fraction-market-sizing

Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5304

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

The market for drug-device combination products is witnessing significant advancements, driven by strategic investments and collaborations. Several recent developments and growth factors highlight the evolving landscape of this sector.

Market Size and Growth Projections

The drug-device combination products market size was estimated at US$ 150.3 billion in 2023 and is projected to grow to US$ 337.81 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.64% from 2024 to 2034. This growth is fueled by the rising incidences of chronic disorders, increasing demand for personalized medicines, and favorable government policies that support market expansion.

Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5290

Key Market Trends

• PCI Pharma Services’ $365 Million Investment: In September 2024, PCI Pharma Services announced a substantial investment exceeding $365 million. This funding is directed towards the development of infrastructure to support the clinical and commercial-scale final assembly and packaging of drug-device combination products. This strategic move underlines the importance of robust infrastructure in meeting the rising demand for these products.
• Freudenberg Medical’s Expansion Plans: In June 2024, Freudenberg Medical, a global Contract Development and Manufacturing Organization (CDMO) for the medical device and biopharma industry, revealed its plans to expand its drug-device combination products business. The company is allocating over $50 million to establish a new Hemotaq AG production facility in Aachen, Germany, signaling a commitment to scaling up production capabilities.
• Sustainability Initiatives by Kindeva Drug Delivery and Orbia Advance Corporation: In December 2023, Kindeva Drug Delivery collaborated with Orbia Advance Corporation to convert existing marketed pressurized Metered Dose Inhaler (pMDI) products to Koura’s sustainable medical propellant, HFA 152a, branded as Zephex 152a. This transition emphasizes the industry’s shift toward environmentally-conscious solutions.

Key Growth Factors

• Rising Incidences of Chronic Disorders: The increasing prevalence of chronic conditions, including cancer, neurological disorders, and autoimmune diseases, drives the demand for innovative drug-device combination products. These solutions offer enhanced treatment options and patient outcomes.
• Advancements in Research and Development: Continuous investments in research and development have led to the creation of novel drug-device combination products. These innovations not only expand the product portfolio but also cater to the unmet needs in healthcare.
• Supportive Regulatory Frameworks: Regulatory agencies worldwide provide clear guidelines for the approval of drug-device combination products, ensuring their safety and efficacy. These frameworks play a crucial role in accelerating product development and market entry.
• Collaborations Among Industry Players: Strategic partnerships and collaborations among pharmaceutical companies, medical device manufacturers, and other stakeholders are facilitating the production and distribution of advanced drug-device combination products. These alliances enable resource sharing and foster innovation.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/drug-device-combination-products-market-sizing

Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5290

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare